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Background: Despite the progressive increase in life expectancy and the relationship between aging with
multi-morbidities and the increased use of healthcare resources, current clinical practice guidelines (CPG) on
cardiometabolic risk cannot be adequately applied to elderly subjects with multiple chronic conditions. Its
management frequently becomes complicated by both, an excessive use of medications that may lead to
overtreatment, drug interactions and increased toxicity, and errors in dosage and non-compliance. Concerned by
this gap, the Spanish Society of Internal Medicine created a group of independent experts on cardiometabolic
risk who discussed what they considered to be unanswered questions in the management of elderly patients.
Discussion: Current guidelines do not specifically address the problem of elderly with multiple chronic conditions.
For this reason, the combined use of the limited available evidence, clinical experience and common sense, could all
help us to address this unmet need. In very old people, life expectancy and functionality are the most important
factors for guiding potential treatments. Their higher propensity to develop serious adverse events and their shorter
lifespan could prevent them from obtaining the potential benefits of the interventions administered.
Summary: In this document, experts on cardiometabolic risk factors have established a number of consensual
recommendations that have taken into account international guidelines and clinical experience, and have also
considered the more effective use of healthcare resources. This document is intended to provide general
recommendations for clinicians and to promote the effective use of procedures and medications.
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In the last years, life expectancy has increased greatly
worldwide. It is estimated that in 2050 the percentage of
individuals over 65 years will represent 27% of the popu-
lation of the European Union [1], and nearly 30% in
Spain [2]. If the current aged-based decrease in the mor-
tality rate is maintained in Spain, life expectancy at birth
could reach 84.3 and 89.9 years in males and females, re-
spectively by 2048 [2].* Correspondence: ricardogomezhuelgas@hotmail.com
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article, unless otherwise stated.Chronic diseases increase with age. According to the
Spanish version of the European Health Interview Survey
(EHIS), 86% of subjects aged 75 or above declare to have
at least one chronic clinical condition [3]. Age and chronic
diseases are closely related to multi-morbidity which in
turn, associates with an increased mortality, a decreased
functional status, a reduced quality of life, and an in-
creased utilization of healthcare resources [4].
Cardiovascular disease (CVD) is the most prevalent
disorder in subjects with various comorbid conditions.
In the PROFUND project, designed to develop a predict-
ive model for patients with multi-morbidity, heart dis-
eases were present in 78% of the study population at
baseline. Moreover, cardiovascular risk factors such asCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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reported among the most frequent comorbidities (71.8,
70.5, 45.6 and 28.9% respectively) [5,6]. In fact, CVD re-
mains the main cause of death at older ages [7,8].
Clinical Practice Guidelines (CPG) have been devel-
oped to help clinicians to improve the management and
quality of care of specific diseases. However, at present,
most CPG cannot be adequately applied to older pa-
tients with multiple chronic conditions. They are mostly
based on clinical data provided by trials that have in-
cluded either a small number of elderly patients or none
at all [7]. Moreover, studies in people older than 80 years
are scarce, despite the fact that they represent an in-
creasing population with a different clinical profile com-
pared with old under 80. Furthermore, CPG generally
provide guidance for managing single conditions, but
they rarely give advice on various chronic conditions at
a time [9]. Aware of these limitations, a comprehensive
statement for the secondary prevention of CVD in older
adults has been recently published [10]. It is also striking
that functionality is usually neglected, either in clinical
studies or in guidelines, despite being a main issue in
the elderly care.
For all these reasons, the management of the elderly is
difficult, frequently complicated by an excessive use of
medications that may lead to overtreatment, increased
toxicity and drug interactions, as well as by errors in
dosage and non-compliance [11]. After considering the
aforementioned factors, and within the framework of
the “Spanish National Health System (SNS) strategy”
for approaching chronicity [12], the Spanish Society
of Internal Medicine (SEMI) has coordinated this expert
panel to analyse some relevant questions related to the
management of the cardio-metabolic risk in elderly pa-
tients. A previous panel was created in November 2012
to address the cardiovascular risk in the general popula-
tion [13]. In this occasion the experts have been asked
to cover this same topic but focused on the elderly,
with the aim of providing a better approach to help cli-
nicians in their daily practice. With this aim, the Clinical
Coordinators of the various Working Groups of the
Spanish Society of Internal Medicine were asked to select
16 specific questions that they considered unresolved or
that could cause uncertainty, in relation to the manage-
ment of dyslipidemia; diabetes, obesity and nutrition; high
blood pressure and antiplatelet therapy in the elderly, four
questions for each topic. After a detailed analysis of the
medical literature, a total of 17 questions (5 related with
the antiplatelet therapy) were initially selected for discus-
sion. During the debate to reach a consensus, one ques-
tion related with diabetes, obesity and nutrition topic was
discarded, leaving a total of 16 questions.
These questions were proposed for discussion to 59
participants (15 participants for each topic), previouslyselected for their extensive knowledge on the topic under
discussion. Participants received relevant bibliography re-
lated to each question in advance which was previously
selected by the specific Coordinator. All questions were
discussed for approximately two hours and answered by
consensus.
We must underscore that this manuscript is not a sys-
tematic review, but rather a statement based on the opin-
ions of experts.
Discussion
The answers to each question are presented here:
Dyslipidemia
Are vascular risk equations useful for estimating the
cardiovascular risk in the elderly Spanish population?
The vascular risk estimation in the elderly must be ad-
dressed by a comprehensive evaluation, including other
important considerations (function, frailty, cognitive state,
quality of life and life expectancy).
There is a lack of large cohorts aimed to estimate the
cardiovascular risk of the Spanish population [14]. For
this reason, the SCORE [14] and the Framingham [15]
risk equations have been calibrated to be used in Spain
[16,17]. Both SCORE and Framingham risk equations,
similarly classify high risk individuals. Nevertheless, and
as suggested by other Spanish Societies, when vascular
risk needs to be estimated the initial use of the adapted
SCORE chart is recommended. Since the age limit estab-
lished for estimating the risk in the SCORE chart is
65 years, older subjects may be allocated in this max-
imum age, even assuming that their risk could be under-
estimated. If the estimated risk is not high according to
the SCORE chart, we recommend the use of the cali-
brated Framingham risk equation in order to avoid miss-
ing the few patients that could be reclassified as high
risk according to this chart. The adapted Framingham
risk equation allows calculations up to 79 years of age,
although we admit it is not adequate to predict cardio-
vascular events in subjects over 80 years of age [18].
We also admit that there is an urgent need to develop
national risk equations that could be applied to sub-
jects of all ages. In the meantime, and considering the
need of estimating the risk in older individuals, we
should use the available risk charts with the chance of
risk underestimation.
Cardiovascular risk scores should never replace clinical
judgment, especially in older patients. An individualized
decision-making process based on functional and cogni-
tive status, quality of life and life expectancy, comorbidi-
ties and the patient’s preferences is critical in the elderly.
Elderly-specific validated scales that include relevant
markers for this population such as frailty and disability,
have to be developed [19].
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Due to the inability of risk charts to predict risk in the
elderly, it should be asked whether age could be consid-
ered a risk factor by itself and, therefore, prompt the ini-
tiation of preventive strategies. In fact, in the case of
elderly patients without known CVD, classical risk fac-
tors do not accurately identify high risk individuals [18].
Although age is an accepted independent cardiovascular
risk factor, not even very elderly subjects should be cate-
gorized as high risk individuals just for their age. Thus
cardiovascular risk evaluation should be recommended
to all age groups [20].
Is statin treatment useful for the primary prevention of CVD
in the elderly?
There are few studies evaluating the efficacy of statins in
the primary prevention of CVD in the elderly. Life ex-
pectancy in Spain at 80 years is approximately 5–6 years
in males and 8 years in females, a sufficient time frame
for obtaining a benefit from statins. In a meta-analysis of
eight randomized trials by Savarese et al. [21], compar-
ing statin treatment vs placebo in subjects over 65 years
without established CVD, statins significantly reduced
the incidence of myocardial infarction (MI) and stroke,
although survival was not significantly prolonged. How-
ever, it must be underscored that this meta-analysis did
not give information about patients older than 80, and
the numbers needed to treat were relatively high (83 for
MI and 142 for stroke).
The panel agreed that the use of statins in primary
prevention may be beneficial, although after considering
the evidence and cost-benefit reasons, they should be
exclusively recommended to high-risk individuals with
good functionality.
Is statin treatment useful for the secondary prevention of
CVD in the elderly?
The evidence of cardiovascular risk reduction with statin
treatment in secondary prevention is clear. Several re-
ports have addressed a similar treatment benefit both in
the elderly and in younger patients [22]. Statins reduce
the risk of MI and stroke, as well as all-cause mortality
in patients over 65 years of age [23,24]. Considering the
evidence, and in accordance with the European recom-
mendations [25], we agree that statins treatment should
be identically considered in both elderly and younger pa-
tients with established CVD.
Diabetes, obesity and nutrition
What would be the recommended glycemic target in elderly
Spanish diabetic patients?
Recent recommendations point out the need of a tai-
lored antidiabetic treatment for older diabetics. When
making treatment decisions, this approach takes intoconsideration, the history of hypoglycemias, comorbidi-
ties, self-care abilities, cognitive decline, functional sta-
tus, and life expectancy [26]. Avoiding hypoglycemias is
critical in this population, since elderly patients are at an
increased risk of hypoglycemia, often the unaware type,
which may have serious consequences (falls and func-
tional and cognitive impairment) [27]. Several guidelines
about the treatment of type 2 diabetes in the elderly
have been recently published [28,29]. Accordingly, the
consensus emphasizes the importance of establishing a
less tight control of glycemic parameters, balancing the
risk/benefit of treatment, and considering the patient
general status [30]. Renal and hepatic impairment and
potential drug interactions should be also taken into ac-
count. The use of sulphonilureas should be restricted in
the elderly, favoring the use of antidiabetic drugs with a
low risk of hypoglycemia (metformin, DPP-4 inhibitors)
[30]. Initiatives such as those of the Institute for Diabetes
in Older People (IDOP) (http://instituteofdiabetes.org) can
be useful for increasing the quality of care in this popula-
tion, including diabetes care at home.
Is there any evidence that intentional weight loss could be
beneficial for overweight/obese elderly diabetic patients?
Diet and exercise are important components for opti-
mizing both general and cardiovascular health in older
adults. Weight loss is generally recommended for redu-
cing comorbid conditions. However, this recommenda-
tion may not be suitable for old patients. On one hand,
sarcopenic obesity is highly prevalent in the elderly [31].
On the other hand, the obesity paradox [32] reminds us
that someone who has achieved old age probably shouldn’t
be encouraged to lose weight. Moreover, in the elderly,
weight loss is associated with a high risk of bone loss re-
lated to energy restriction, and decreased nutrient intake.
Therefore, very restrictive diets must be avoided in the
elderly. Protein intake should be at least 0.8 g/kg body
weight unless there was severe renal impairment [33].
The Mediterranean diet gives an adequate dietary fiber
amount and low saturated fats, and has shown favor-
able effects on cardiovascular risk factors and outcomes
in older adults [34]. Vitamin D deficiency is also very
common in this population [35] and has been identified
as an independent risk factor for cardiovascular mortality
in older adults [36]. Hence, the strategy for this popula-
tion should be to recommend a combination of physical
activity and nutritional therapy, including a higher intake
of calcium, vitamin D and other nutrients [37].
Increasing physical activity in older adults should reduce
sedentary behavior and emphasize moderate-intensity aer-
obic activity. The activity plan must take into account the
older adult’s abilities and aerobic fitness. Activities aimed
to increase flexibility, muscle-strengthening and balance
are also recommended [38].
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diabetic patients?
Malnutrition is an important problem in the ageing popu-
lation with potential serious consequences. Several studies
have found a relationship between malnutrition and, pro-
longed hospitalization, increased costs, and higher number
of readmissions. Therefore, early detection and manage-
ment of malnutrition is crucial in order to prevent future
complications [39]. A number of screening tools are
already available to assess nutritional status. Although
not specifically focused on geriatric people, they can be
administered to the elderly because of their simplicity,
speed and easy design [40].
High blood pressure
Which blood pressure targets should be applied to the
elderly population?
It is difficult to make recommendations about how to
manage high blood pressure (BP) in older adults. Most
of the information has been largely obtained from stud-
ies of isolated systolic hypertension and only one study
has included people over 80 years [41]. On the other
hand, the age-related increase in systolic BP could be
considered a physiological phenomenon that usually goes
together with a diastolic BP decrease [42]. Various meta-
analyses confirmed a differential effect of antihypertensive
drugs on morbidity and mortality in relation to age
(65–79 vs. 80 or older). In subjects older than 79 years,
antihypertensive drugs reduce nonfatal vascular events
(mainly strokes), but increase total mortality when the
diastolic BP decrease below 70 mmHg [43,44]. Some epi-
demiological studies showed a J shaped relationship be-
tween BP and the incidence of cardiovascular events [45],
with different systolic and diastolic BP nadir values when
comparing subjects between 65–79 years of age with
those aged 80 years or older [46].
It is acknowledged that for hypertensive subjects aged
65 to 79 years, the evidence obtained from younger
adults should be applied. However, that should not be the
case for people over 79 years, where there is no evidence,
neither from clinical trials nor from meta-analysis, of the
optimum blood pressure targets. It is also acknowledged
that BP targets must be established according to the func-
tional status, not just the age, and that a general BP target
could be 140/90 mmHg, always avoiding a diastolic BP
lower than 75–80 mmHg.
Which should be the first drug to be use in elderly
hypertensive patients?
There is a lack of studies comparing various antihyper-
tensive drugs in older individuals. Although the benefi-
cial effects of the antihypertensive drugs shown in the
meta-analysis are similar to the ones obtained in youn-
ger adults, it should be emphasized that no previousmeta-analysis has included people older than 80 years,
or considered their frailty/functional status [47].
Taking all these aspects into consideration, angiotensin-
converting-enzyme inhibitors, calcium channel blockers
and their fixed combinations, should probably be the best
pharmacological options due to their better tolerability. Ini-
tial lower doses and a slower titration should be recom-
mended in elderly patients in order to avoid adverse events
and a negative impact on quality of life and functionality.
Beyond blood pressure, which aspects should be considered
when making decisions about antihypertensive treatment in
elderly patients?
Most clinical guidelines acknowledged that, in many as-
pects, there is a lack of evidence on hypertension man-
agement in the elderly. They usually point out that when
speaking about elder individuals, there are no proper
guidelines but rather consensual documents. All these
guidelines have also emphasized that functionality, co-
morbidity and life expectancy, are more relevant indica-
tors for choosing a treatment than just age [48-50]. A
recent study has shown that for an elderly hypertensive
population, frailty is one of the strongest predictors of
mortality [51]. Despite this, there is no specific trial on
antihypertensive treatment focusing on functional status
rather than on age.
Would ambulatory blood pressure monitoring (ABMP) have
a specific role in elderly hypertensive patients?
ABPM could be specially indicated in this population. In
the very old, as showed in the HYVET substudy, white
coat hypertension is present in at least 50% of subjects
[52]. Due to this high prevalence of white coat hyperten-
sion and to the risk of diastolic hypotension when trying to
control systolic BP, ABPM should be specially considered
to ensure diagnosis and for an accurate individualization of
pharmacological treatment [53].
Antiplatelet therapy
When is antiplatelet therapy indicated in elderly patients
without CVD?
The use of aspirin in primary prevention confers a mod-
est benefit in nonfatal MI and CVD events and greatly
increases the risk of bleeding associated with aspirin.
For this reason, the risk/benefit ratio for recommending
its use, should be carefully evaluated on a patient by pa-
tient basis [54].
Is antiplatelet therapy a more reasonable (risk/benefit)
alternative than anticoagulation in elderly patients with
atrial fibrillation?
Overall, anticoagulation (with anti vitamin K or new oral
anticoagulants) provide a net benefit over antiplatelet
therapy in elderly patients with atrial fibrillation. One
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tients with CHADS-VASc = 1, especially if they have a
high bleeding risk (HAS-BLED > =3).
Due to the higher risk of major bleeding associated
with anticoagulation, the selection of antithrombotic ther-
apy in this population should balance the risk for embol-
ism and the risk for hemorrhage. In this setting the use
of CHADs-VASC and HAS-BLEED scores is mandatory.
The net clinical benefit is higher in subjects with a higher
risk of stroke, including the oldest age category, despite
their higher bleeding risk [55].
Is there any indication for dual antiplatelet therapy in
the elderly?
Dual antiplatelet therapy, usually aspirin and clopidogrel,
is a general recommendation in patients with an acute
coronary syndrome and after percutaneous coronary inter-
ventions [56,57]. In the CURE trial [58], the addition of
clopidogrel to aspirin showed similar absolute reductions
(although smaller relative reductions) in the combined ische-
mic end points, in older as compared to younger patients.
Is there any indication for both antiplatelet therapy and
anticoagulation in the elderly?
The addition of antiplatelet therapy to anticoagulants
in older patients, is indicated in the same clinical condi-
tions that are recommended in younger individuals (such
as atrial fibrillation plus coronary stent placement), al-
ways taking into account the higher risk of bleeding at
this age [57].
Does aging involve any exceptions regarding the general
recommendations on antiplatelet therapy in CVD?
In general, aging alone is not a contraindication to fol-
low the general recommendations on antiplatelet therapy
in CVDs, although treatment decisions should always con-
sider life expectancy and functional status.
The evaluation of both CHADS-VASc and HAS-BLED
is very important in the elderly, although patients with a
high CHADs-VASC usually have also a high HAS-BLED.
Summary
There is a general perception of a gap in the current car-
diovascular guidelines, which do not specifically address
the problem of the elderly with multiple chronic condi-
tions. For this reason, interpretation of the scarce avail-
able evidence, clinical experience and common sense,
should be taken into consideration when addressing this
unmet need. For very old people, life expectancy as well
as functionality are the most important issues to be con-
sidered, mainly because older subjects are prone to fre-
quent adverse events and their lifespan could prevent
them from achieving the potential benefits of the inter-
ventions administered.This document provides some consensual recommen-
dations about general unanswered questions in cardio-
metabolic risk in the elderly. International guidelines
and clinical experience have been considered as well as
the most effective use of health care resources. Far from
trying to increase the available information, this docu-
ment is intended to provide general recommendations
for clinicians and to promote the effective use of proce-
dures and medications. We must underscore that this
manuscript is not a systematic review, but rather a state-
ment based on the opinions of experts.
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